AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

- 1.-8. (Canceled)
- (Currently Amended) A method for producing human Tr1-like regulatory cells, which method comprises the steps of:
 - (a)—anergizing CD4⁺ CD25⁻ T cells by contacting the CD4⁺ CD25⁻ T cells with activated CD4⁺ CD25⁺ T cells ex vivo or in vivo to yield human Tr1-like regulatory cells; and
 - (b) separating human Tr1 like regulatory cells from the CD4+CD25+T cells.
 - 10. (Canceled)
- 11. (Currently Amended) The method of claim 9, wherein step (a) of said

 method-contacting comprises coculturing the CD4⁺ CD25⁻ T cells with the CD4⁺ CD25⁺

 T cells.
 - 12.-28. (Canceled)
- 29. (Previously Presented) The method of claim 9, wherein said Tr1-like regulatory cells produce IL-10.

 (Previously Presented) The method of claim 29, wherein said Tr1-like regulatory cells suppress the proliferation of syngeneic CD4⁺T cells.

31,-34. (Canceled)

- 35. (Previously Presented) The method of claim 9, which comprises anergizing CD4⁺ CD25⁻ T cells by contacting the CD4⁺ CD25⁻ T cells with the CD4⁺ CD25⁺ T cells ex vivo.
- 36. (Withdrawn) The method of claim 9, which comprises anergizing CD4⁺ CD25⁻ T cells by contacting the CD4⁺ CD25⁻ T cells with the CD4⁺ CD25⁺ T cells *in*
- 37. (Previously Presented) The method according to claim 9, which further comprises producing the activated CD4⁺ CD25⁺ T cells by subjecting unactivated CD4⁺ CD25⁺ T cells to plate-bound anti-CD3 and soluble anti-CD28 antibodies.
- 38. (Withdrawn) The method according to claim 9, which further comprises producing the activated CD4⁺ CD25⁺ T cells by subjecting unactivated CD4⁺ CD25⁺ T cells to mature dendritic cells.